Cannabis-pill firm () is launching a new communications strategy and has hired Mackie Research as financial advisor and Hybrid Financial Ltd to assist with investor relations.
In a regulatory release, the company reminded investors that it listed on the Canadian Securities Exchange in April this year.
"Management is pleased with the company's operational progress since its public listing and feels that it is time to turn a greater attention to growing awareness of the company, its activities and the unique business opportunities being developed in the medicinal cannabis markets, and potentially in the recreational cannabis markets — both in Canada and Internationally," it said.
The business plan has focused on receiving Health Canada approval for research and development (R&D) on oral sustained release formulations of Canntab's cannabinoids products, which it achieved in May.
It also filed new patent applications related to its intellectual property (IP) portfolio.
In July, it also announced a profit-sharing collaboration with medical pot producer Inc.
Under the letter of intent (LOI), will help Canntab to obtain a license to process and sell cannabis products under the new legislation.
Canntab will pay a monthly, non-refundable work fee of C$20,000 to Mackie Research and grant 200,000 options to the group.
It will also pay a monthly fee of $14,000 to Hybrid; and grant 250,000 options to Hybrid.
Shares in Canntab were unchanged at C$1.02.